Education
About Us
Working with TipRanks
Follow Us
Scandion Oncology A/S (SE:SCOL)
:SCOL
RESEARCH TOOLSreports
Top Page
Scandion Oncology A/S
(Frankfurt:SCOL)
31Underperform
Scandion Oncology A/S (SCOL) vs. S&P 500 (SPY)
Market Cap
kr2.49M
Dividend YieldN/A
Average Volume (3M)9.40M
Price to Earnings (P/E)―
Beta (1Y)0.14
Revenue GrowthN/A
EPS Growth57.91%
CountrySE
Employees10
SectorHealthcare
Sector Strength65
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.35
Shares Outstanding234,761,410
10 Day Avg. Volume2,343,768
30 Day Avg. Volume9,395,297
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Scandion Oncology A/S Business Overview & Revenue Model
Company DescriptionScandion Oncology A/S (SCOL) is a biotechnology company specializing in developing innovative treatments to overcome drug resistance in cancer therapy. The company focuses on creating and advancing pharmaceutical solutions that enhance the effectiveness of existing cancer treatments. Scandion Oncology's core product portfolio includes proprietary drug candidates designed to counteract resistance mechanisms in cancer cells, thus improving patient outcomes in oncology sectors.
How the Company Makes MoneyScandion Oncology A/S makes money through the development and commercialization of its drug candidates aimed at reversing cancer drug resistance. The company's revenue model primarily involves research and development collaborations, licensing agreements, and potential milestone payments from pharmaceutical partners. These partnerships can include upfront payments, research funding, and royalties on the sales of successfully marketed drugs. Additionally, Scandion Oncology may receive governmental or institutional grants to support their innovative research efforts. As the company's drug candidates progress through clinical trials and achieve regulatory approvals, these financial streams become crucial in driving growth and sustaining operations.
Scandion Oncology A/S Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 205.44K | Gross Profit |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -11.16M | EBIT |
| -38.31M | -45.36M | -80.17M | -55.37M | -22.89M | -15.39M | EBITDA |
| -37.46M | -45.53M | -80.82M | -56.10M | -22.85M | -15.60M | Net Income Common Stockholders |
| -32.47M | -39.20M | -76.70M | -51.70M | -16.27M | -12.18M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 26.52M | 26.52M | 77.61M | 105.71M | 5.81M | 15.42M | Total Assets |
| 34.56M | 34.56M | 89.40M | 116.22M | 186.41M | 19.90M | Total Debt |
| 499.00K | 499.00K | 1.60M | 1.22M | 316.00K | 1.42K | Net Debt |
| -26.02M | -26.02M | -76.01M | -104.49M | -5.50M | -15.42M | Total Liabilities |
| 3.44M | 3.44M | 19.07M | 11.68M | 30.54M | 1.56M | Stockholders Equity |
| 31.12M | 31.12M | 70.33M | 104.54M | 155.87M | 18.34M |
| Cash Flow | Free Cash Flow | ||||
| -35.72M | -50.67M | -69.86M | -50.12M | -17.50M | -10.20M | Operating Cash Flow |
| -35.72M | -50.67M | -69.44M | -49.80M | -17.45M | -9.96M | Investing Cash Flow |
| 510.00K | 288.00K | -389.00K | -485.00K | -46.00K | -238.28K | Financing Cash Flow |
| 13.69M | -705.00K | 41.73M | 150.18M | 7.89M | 17.95M |
Scandion Oncology A/S Technical Analysis
Negative
0.01
Price Trends
0.03
Negative
0.05
Negative
0.10
Negative
Market Momentum
>-0.01
Negative
36.12
Neutral
25.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCOL, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.03, and below the 200-day MA of 0.10, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 36.12 is Neutral, neither overbought nor oversold. The STOCH value of 25.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SCOL.
Scandion Oncology A/S Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $5.31B | 3.33 | -39.82% | 2.92% | 17.95% | 1.84% | |
49 Neutral | kr46.73M | ― | -47.01% | ― | -94.12% | -25.83% | |
44 Neutral | €77.76M | ― | -96.58% | ― | 30.02% | -3985.71% | |
39 Underperform | €221.04M | ― | ― | 5303.85% | 55.59% | ||
35 Underperform | €3.34M | ― | -41.88% | ― | ― | 94.98% | |
31 Underperform | kr2.49M | ― | -186.04% | ― | ― | 57.91% |
* Healthcare Sector Average
Performance Comparison
SE:SCOL
Scandion Oncology A/S
0.01
-0.83
-98.69%
SE:COMBI
CombiGene AB
2.41
-1.36
-36.07%
SE:LIDDS
LIDDS AB
0.05
-0.11
-67.92%
SE:SPRINT
Sprint Bioscience AB
0.66
-0.61
-47.95%
SE:XINT
Xintela AB
0.33
0.05
18.15%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.